CONMED Competitors

CONMED (NYSE:CNMD) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares CONMED and Varian Medical Systems' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares CONMED and Varian Medical Systems' gross revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than CONMED. Varian Medical Systems is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CONMED has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 5.4% of CONMED shares are held by insiders. Comparatively, 0.8% of Varian Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for CONMED and Varian Medical Systems, as provided by MarketBeat.com.

CONMED presently has a consensus target price of $117.3333, indicating a potential downside of 18.09%. Varian Medical Systems has a consensus target price of $177.70, indicating a potential upside of 0.36%. Given Varian Medical Systems' higher probable upside, analysts clearly believe Varian Medical Systems is more favorable than CONMED.

Summary

Varian Medical Systems beats CONMED on 10 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Masimo and CONMED's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Masimo and CONMED's revenue, earnings per share and valuation.

Masimo has higher earnings, but lower revenue than CONMED. CONMED is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Masimo and CONMED, as reported by MarketBeat.

Masimo currently has a consensus price target of $291.50, indicating a potential upside of 34.41%. CONMED has a consensus price target of $117.3333, indicating a potential downside of 18.09%. Given Masimo's higher probable upside, research analysts clearly believe Masimo is more favorable than CONMED.

Volatility & Risk

Masimo has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by insiders. Comparatively, 5.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Masimo beats CONMED on 11 of the 13 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares LivaNova and CONMED's top-line revenue, earnings per share (EPS) and valuation.

CONMED has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LivaNova and CONMED's net margins, return on equity and return on assets.

Institutional and Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Comparatively, 5.4% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for LivaNova and CONMED, as provided by MarketBeat.com.

LivaNova currently has a consensus target price of $87.75, indicating a potential upside of 5.85%. CONMED has a consensus target price of $117.3333, indicating a potential downside of 18.09%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than CONMED.

Volatility & Risk

LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Summary

CONMED beats LivaNova on 8 of the 13 factors compared between the two stocks.

CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares CONMED and InMode's gross revenue, earnings per share (EPS) and valuation.

InMode has lower revenue, but higher earnings than CONMED. InMode is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CONMED and InMode's net margins, return on equity and return on assets.

Institutional & Insider Ownership

35.7% of InMode shares are held by institutional investors. 5.4% of CONMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for CONMED and InMode, as reported by MarketBeat.com.

CONMED presently has a consensus price target of $117.3333, indicating a potential downside of 18.09%. InMode has a consensus price target of $80.25, indicating a potential upside of 10.66%. Given InMode's stronger consensus rating and higher possible upside, analysts clearly believe InMode is more favorable than CONMED.

Volatility & Risk

CONMED has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.

Summary

InMode beats CONMED on 11 of the 14 factors compared between the two stocks.

CONMED (NYSE:CNMD) and Outset Medical (NASDAQ:OM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares CONMED and Outset Medical's gross revenue, earnings per share (EPS) and valuation.

CONMED has higher revenue and earnings than Outset Medical.

Profitability

This table compares CONMED and Outset Medical's net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.6% of Outset Medical shares are held by institutional investors. 5.4% of CONMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for CONMED and Outset Medical, as reported by MarketBeat.com.

CONMED presently has a consensus price target of $117.3333, indicating a potential downside of 18.09%. Outset Medical has a consensus price target of $58.20, indicating a potential upside of 18.17%. Given Outset Medical's higher possible upside, analysts clearly believe Outset Medical is more favorable than CONMED.

Summary

CONMED beats Outset Medical on 6 of the 9 factors compared between the two stocks.

CONMED (NYSE:CNMD) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Profitability

This table compares CONMED and BioLife Solutions' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares CONMED and BioLife Solutions' gross revenue, earnings per share (EPS) and valuation.

CONMED has higher revenue and earnings than BioLife Solutions. CONMED is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CONMED has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for CONMED and BioLife Solutions, as reported by MarketBeat.

CONMED presently has a consensus price target of $117.3333, indicating a potential downside of 18.09%. BioLife Solutions has a consensus price target of $46.6667, indicating a potential upside of 51.02%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than CONMED.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Comparatively, 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

BioLife Solutions beats CONMED on 8 of the 13 factors compared between the two stocks.